Travoprost
Who holds supplier records for Travoprost? 12 organisations hold a current record for Travoprost: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (3), Taiwan (2), Czechia (1), Argentina (1) and 4 other countries (4); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Travoprost: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/travoprost
Reading the evidence
- 12 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Travoprost expires 14 Feb 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (12)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Travoprost. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CHIROGATE INTERNATIONAL INCTaiwanActive DMF 32964, 22738 · latest filing Jul 2018
- CAYMAN PHARMA SROCzechia Company GMP cert on recordActive DMF 22289 · latest filing Dec 2008
- DELTA BIOTECH SAArgentinaActive DMF 26180 · latest filing Jun 2012
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 14890 · latest filing May 2000
- EUROAPI HUNGARY LTDHungaryActive DMF 29418, 34742 · latest filing Dec 2020
- GENTEC SABelgiumActive DMF 34370 · latest filing Jan 2020
- Lupin LimitedIndia Company GMP cert on recordActive DMF 26878 · latest filing Apr 2013
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 27863 · latest filing Jan 2014
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 23423 · latest filing Dec 2009
- VERANOVA LPUnited KingdomActive DMF 22088 · latest filing Oct 2008
- YS LIFE SCIENCE CO LTDActive DMF 24907 · latest filing Apr 2011
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 40018 · latest filing May 2024
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (3)
Organisations whose Type II DMFs for Travoprost are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- PATHEON API MANUFACTURING INCInactive DMF 28414 · filed Oct 2014
- India · Inactive DMF 25703 · filed Apr 2012
- Taiwan · Inactive DMF 25263 · filed Sept 2011
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Travoprost). The latest listed patent expires 14 Feb 2031. The latest listed exclusivity runs to 13 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Travoprost is a prostaglandin analog used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by increasing the outflow of aqueous humor from the eyes.
Chemical identity
- IUPAC name
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
- Canonical SMILES
- CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
- InChIKey
- MKPLKVHSHYCHOC-AHTXBMBWSA-N
- Synonyms
- Travatan API, al-6221, duotrav component travoprost, idose tr, izba, nsc-760366, otx-tp, travatan
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Prostaglandin Analog
- Chemical structure
- Prostaglandins
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Travoprost?
12 organisations hold an active US FDA Type II Drug Master File or a CEP for Travoprost: CHIROGATE INTERNATIONAL INC (Taiwan), CAYMAN PHARMA SRO (Czechia), DELTA BIOTECH SA (Argentina), Dr. Reddy's Laboratories Ltd. (India), EUROAPI HUNGARY LTD (Hungary), GENTEC SA (Belgium), Lupin Limited (India) and MSN Laboratories Private Limited (India), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Travoprost Drug Master Files are active?
CHIROGATE INTERNATIONAL INC (DMF 32964, 22738), CAYMAN PHARMA SRO (DMF 22289), DELTA BIOTECH SA (DMF 26180), Dr. Reddy's Laboratories Ltd. (DMF 14890), EUROAPI HUNGARY LTD (DMF 29418, 34742), GENTEC SA (DMF 34370), Lupin Limited (DMF 26878) and MSN Laboratories Private Limited (DMF 27863) and 4 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Travoprost records mean?
3 organisations have only inactive Type II DMFs for Travoprost. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Travoprost?
Yes. The latest patent listed for an approved US product containing Travoprost expires 14 Feb 2031, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Travoprost supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Travoprost?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.